The present technology is related to catheters. In particular, at least some embodiments are related to neuromodulation catheters including neuromodulation elements configured to deliver energy to nerves at or near a treatment location within a body lumen.
The sympathetic nervous system (SNS) is a primarily involuntary bodily control system typically associated with stress responses. Fibers of the SNS extend through tissue in almost every organ system of the human body and can affect characteristics such as pupil diameter, gut motility, and urinary output. Such regulation can have adaptive utility in maintaining homeostasis or in preparing the body for rapid response to environmental factors. Chronic activation of the SNS, however, is a common maladaptive response that can drive the progression of many disease states. Excessive activation of the renal SNS, in particular, has been identified experimentally and in humans as a likely contributor to the complex pathophysiologies of hypertension, states of volume overload (e.g., heart failure), and progressive renal disease.
Sympathetic nerves of the kidneys terminate in the renal blood vessels, the juxtaglomerular apparatus, and the renal tubules, among other structures. Stimulation of the renal sympathetic nerves can cause, for example, increased renin release, increased sodium reabsorption, and reduced renal blood flow. These and other neural-regulated components of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone. For example, reduced renal blood flow and glomerular filtration rate as a result of renal sympathetic efferent stimulation is likely a cornerstone of the loss of renal function in cardio-renal syndrome (i.e., renal dysfunction as a progressive complication of chronic heart failure). Pharmacologic strategies to thwart the consequences of renal sympathetic stimulation include centrally-acting sympatholytic drugs, beta blockers (e.g., to reduce renin release), angiotensin-converting enzyme inhibitors and receptor blockers (e.g., to block the action of angiotensin II and aldosterone activation consequent to renin release), and diuretics (e.g., to counter renal sympathetic mediated sodium and water retention). These pharmacologic strategies, however, have significant limitations including limited efficacy, compliance issues, side effects, and others.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. For ease of reference, throughout this disclosure identical reference numbers may be used to identify identical or at least generally similar or analogous components or features.
Specific details of systems, devices, and methods in accordance with several embodiments of the present technology are disclosed herein with reference to
As used herein, the terms “distal” and “proximal” define a position or direction with respect to a clinician or a clinician's control device (e.g., a handle of a catheter). The terms, “distal” and “distally” refer to a position distant from or in a direction away from a clinician or a clinician's control device. The terms “proximal” and “proximally” refer to a position near or in a direction toward a clinician or a clinician's control device. The headings provided herein are for convenience only and should not be construed as limiting the subject matter disclosed.
Selected Examples of Neuromodulation Catheters and Related Systems and Devices
Intraluminal delivery of the catheter 102 can include percutaneously inserting a guide wire (not shown) into a body lumen of a patient and moving the shaft 108 and the neuromodulation element 112 along the guide wire until the neuromodulation element 112 reaches a suitable treatment location. Alternatively, the catheter 102 can be a steerable or non-steerable device configured for use without a guide wire. As another alternative, the neuromodulation catheter 102 can be configured for use with a guide catheter or sheath (not shown). In the illustrated embodiment, the console 104 is configured to control, monitor, supply, and/or otherwise support operation of the catheter 102. In other embodiments, the catheter 102 can be self-contained or otherwise configured for operation independent of the console 104. When present, the console 104 can be configured to generate a selected form and/or magnitude of energy for delivery to tissue at a treatment location via the neuromodulation element 112. For example, the console 104 can be configured to generate radio frequency (RF) energy (e.g., monopolar and/or bipolar RF energy) and/or another suitable type of energy for delivery to tissue at a treatment location via electrodes (not shown) of the neuromodulation element 112. Along the cable 106 or at another suitable location within the system 100, the system 100 can include a control device 114 configured to initiate, terminate, and/or adjust operation of one or more components of the catheter 102 directly and/or via the console 104. The console 104 can be configured to execute an automated control algorithm 116 and/or to receive control instructions from an operator. Similarly, the console 104 can be configured to provide feedback to an operator before, during, and/or after a treatment procedure via an evaluation/feedback algorithm 118.
The shaft 108 can include an assembly of parallel tubular segments. At its proximal end portion 108a and extending distally though a majority of its intermediate portion 108c, the shaft 108 can include a proximal hypotube segment 128, a proximal jacket 130, a first electrically insulative tube 132, and a guide-wire tube 134. The first electrically insulative tube 132 and the guide-wire tube 134 can be disposed side-by-side within the proximal hypotube segment 128. The first electrically insulative tube 132 can be configured to carry electrical leads (not shown) and to electrically insulate the electrical leads from the proximal hypotube segment 128. The guide-wire tube 134 can be configured to carry a guide wire (not shown). The proximal jacket 130 can be disposed around at least a portion of an outer surface of the proximal hypotube segment 128. The proximal hypotube segment 128 can include a proximal stem 136 at its proximal end and a distal skive 138 at its distal end. The proximal jacket 130 and the proximal hypotube segment 128 are discussed in greater detail below with reference to
With reference again to
The neuromodulation element 112 can include a distal hypotube segment 142 coupled to the distal end of the intermediate tube 140. The neuromodulation element 112 can also include a distal jacket 144 disposed around at least a portion of an outer surface of the distal hypotube segment 142. As shown, the neuromodulation element 112 can further include band electrodes 146 disposed outside the distal jacket 144 at spaced-apart positions along a longitudinal axis of the distal jacket 144. At a distal end of the distal hypotube segment 142, the neuromodulation element 112 can include a distally tapering atraumatic tip 148. The guide-wire tube 134 can extend through the distal hypotube segment 142 to a distal opening 150 of the tip 148. The electrical leads can respectively extend through the distal hypotube segment 142 to the band electrodes 146.
In
With reference to
A maximum outer diameter of the band electrodes 204 and the maximum outer diameter of the distal jacket 200 between the reduced-diameter segments 202 can be at least generally equal (e.g., within 5%, 3%, or 2% of one another). Thus, once the band electrodes 204 are respectively seated in the reduced-diameter segments 202, outer surfaces of the band electrodes 204 and the distal jacket 200 between the reduced-diameter segments 202 can be at least generally flush. This can be useful, for example, to reduce or eliminate potentially problematic ridges (e.g., circumferential steps) at distal and proximal ends of the individual band electrodes 204. This, in turn, can reduce or eliminate the need for fillets (e.g., adhesive fillets, such as glue fillets) at the distal and proximal ends of the individual band electrodes 204. In at least some embodiments, the distal jacket 200 and the band electrodes 204 can be bonded to one another without any exposed adhesive. For example, an adhesive (not shown) can be disposed between the band electrodes 204 and the distal jacket 200 at the reduced-diameter segments 202.
Sidewall configurations different than the configuration shown in
Selected Examples of Manufacturing Methods for Neuromodulation Elements
The method 500 can further include jacketing the distal hypotube segment 142 (block 508), such as by positioning the distal jacket 200 and the distal hypotube segment 142 relative to one another so that the distal jacket 200 is disposed around at least a portion of an outer surface of the distal hypotube segment 142. In at least some embodiments, the form and/or other aspects of the distal jacket 200 may allow the distal jacket 200 to be disposed around at least a portion of the outer surface of the distal hypotube segment 142 without swaging the distal jacket 200. When the distal hypotube segment 142 is positioned within the distal jacket 200, the method 500 can include respectively stringing electrical leads (block 510) from the reduced-diameter segments 202 through a lumen of the distal hypotube segment 142. Next, the method 500 can include dispensing an adhesive (block 512) onto the distal jacket 200 at the reduced-diameter segment 202d. Then, the method 500 can include positioning the band electrode 204d (block 514) at the reduced-diameter segment 202d. As discussed above with reference to
Renal Neuromodulation
Catheters configured in accordance with at least some embodiments of the present technology can be well suited (e.g., with respect to sizing, flexibility, operational characteristics, and/or other attributes) for performing renal neuromodulation in human patients. Renal neuromodulation is the partial or complete incapacitation or other effective disruption of nerves of the kidneys (e.g., nerves terminating in the kidneys or in structures closely associated with the kidneys). In particular, renal neuromodulation can include inhibiting, reducing, and/or blocking neural communication along neural fibers (e.g., efferent and/or afferent neural fibers) of the kidneys. Such incapacitation can be long-term (e.g., permanent or for periods of months, years, or decades) or short-term (e.g., for periods of minutes, hours, days, or weeks). Renal neuromodulation is expected to contribute to the systemic reduction of sympathetic tone or drive and/or to benefit at least some specific organs and/or other bodily structures innervated by sympathetic nerves. Accordingly, renal neuromodulation is expected to be useful in treating clinical conditions associated with systemic sympathetic overactivity or hyperactivity, particularly conditions associated with central sympathetic overstimulation. For example, renal neuromodulation is expected to efficaciously treat hypertension, heart failure, acute myocardial infarction, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic and end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, polycystic kidney disease, polycystic ovary syndrome, osteoporosis, erectile dysfunction, and sudden death, among other conditions.
Renal neuromodulation can be electrically-induced, thermally-induced, or induced in another suitable manner or combination of manners at one or more suitable treatment locations during a treatment procedure. The treatment location can be within or otherwise proximate to a renal lumen (e.g., a renal artery, a ureter, a renal pelvis, a major renal calyx, a minor renal calyx, or another suitable structure), and the treated tissue can include tissue at least proximate to a wall of the renal lumen. For example, with regard to a renal artery, a treatment procedure can include modulating nerves in the renal plexus, which lay intimately within or adjacent to the adventitia of the renal artery. Various suitable modifications can be made to the catheters described above to accommodate different treatment modalities. For example, the band electrodes 204 (
Renal neuromodulation can include an electrode-based or treatment modality alone or in combination with another treatment modality. Electrode-based or transducer-based treatment can include delivering electricity and/or another form of energy to tissue at or near a treatment location to stimulate and/or heat the tissue in a manner that modulates neural function. For example, sufficiently stimulating and/or heating at least a portion of a sympathetic renal nerve can slow or potentially block conduction of neural signals to produce a prolonged or permanent reduction in renal sympathetic activity. A variety of suitable types of energy can be used to stimulate and/or heat tissue at or near a treatment location. For example, neuromodulation in accordance with embodiments of the present technology can include delivering RF energy, pulsed electrical energy, microwave energy, optical energy, focused ultrasound energy (e.g., high-intensity focused ultrasound energy), and/or another suitable type of energy. An electrode or transducer used to deliver this energy can be used alone or with other electrodes or transducers in a multi-electrode or multi-transducer array.
Neuromodulation using focused ultrasound energy (e.g., high-intensity focused ultrasound energy) can be beneficial relative to neuromodulation using other treatment modalities. Focused ultrasound is an example of a transducer-based treatment modality that can be delivered from outside the body. Focused ultrasound treatment can be performed in close association with imaging (e.g., magnetic resonance, computed tomography, fluoroscopy, ultrasound (e.g., intravascular or intraluminal), optical coherence tomography, or another suitable imaging modality). For example, imaging can be used to identify an anatomical position of a treatment location (e.g., as a set of coordinates relative to a reference point). The coordinates can then entered into a focused ultrasound device configured to change the power, angle, phase, or other suitable parameters to generate an ultrasound focal zone at the location corresponding to the coordinates. The focal zone can be small enough to localize therapeutically-effective heating at the treatment location while partially or fully avoiding potentially harmful disruption of nearby structures. To generate the focal zone, the ultrasound device can be configured to pass ultrasound energy through a lens, and/or the ultrasound energy can be generated by a curved transducer or by multiple transducers in a phased array, which can be curved or straight.
Heating effects of electrode-based or transducer-based treatment can include ablation and/or non-ablative alteration or damage (e.g., via sustained heating and/or resistive heating). For example, a treatment procedure can include raising the temperature of target neural fibers to a target temperature above a first threshold to achieve non-ablative alteration, or above a second, higher threshold to achieve ablation. The target temperature can be higher than about body temperature (e.g., about 37° C.) but less than about 45° C. for non-ablative alteration, and the target temperature can be higher than about 45° C. for ablation. Heating tissue to a temperature between about body temperature and about 45° C. can induce non-ablative alteration, for example, via moderate heating of target neural fibers or of luminal structures that perfuse the target neural fibers. In cases where luminal structures are affected, the target neural fibers can be denied perfusion resulting in necrosis of the neural tissue. Heating tissue to a target temperature higher than about 45° C. (e.g., higher than about 60° C.) can induce ablation, for example, via substantial heating of target neural fibers or of luminal structures that perfuse the target fibers. In some patients, it can be desirable to heat tissue to temperatures that are sufficient to ablate the target neural fibers or the luminal structures, but that are less than about 90° C. (e.g., less than about 85° C., less than about 80° C., or less than about 75° C.).
Conclusion
This disclosure is not intended to be exhaustive or to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without deviating from the present technology, as those of ordinary skill in the relevant art will recognize. In some cases, well-known structures and functions have not been shown and/or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of methods may be presented herein in a particular order, in alternative embodiments the steps may have another suitable order. Similarly, certain aspects of the present technology disclosed in the context of particular embodiments can be combined or eliminated in other embodiments. Furthermore, while advantages associated with certain embodiments may have been disclosed in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages or other advantages disclosed herein to fall within the scope of the present technology. Accordingly, this disclosure and associated technology can encompass other embodiments not expressly shown and/or described herein.
The methods disclosed herein include and encompass, in addition to methods of practicing the present technology (e.g., methods of making and using the disclosed devices and systems), methods of instructing others to practice the present technology. For example, a method in accordance with a particular embodiment includes forming a tubular jacket, resiliently deforming the jacket inwardly while passing the jacket through a channel of a band electrode, and positioning the jacket and a hypotube segment relative to one another so that the jacket is disposed around at least a portion of an outer surface of the hypotube segment. A method in accordance with another embodiment includes instructing such a method.
Throughout this disclosure, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. Similarly, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout this disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or one or more additional types of features are not precluded. Directional terms, such as “upper,” “lower,” “front,” “back,” “vertical,” and “horizontal,” may be used herein to express and clarify the relationship between various elements. It should be understood that such terms do not denote absolute orientation. Reference herein to “one embodiment,” “an embodiment,” or similar formulations means that a particular feature, structure, operation, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present technology. Thus, the appearances of such phrases or formulations herein are not necessarily all referring to the same embodiment. Furthermore, various particular features, structures, operations, or characteristics may be combined in any suitable manner in one or more embodiments of the present technology.
This application is a continuation of U.S. patent application Ser. No. 14/606,821, filed on Jan. 27, 2015, and entitled, “NEUROMODULATION CATHETERS HAVING JACKETED NEUROMODULATION ELEMENTS AND RELATED DEVICES, SYSTEMS, AND METHODS,” which claims the benefit of U.S. Provisional Patent Application No. 61/932,224, filed on Jan. 27, 2014, the disclosure of each which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4602624 | Naples et al. | Jul 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4764504 | Johnson et al. | Aug 1988 | A |
4890623 | Cook et al. | Jan 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
4998923 | Samson et al. | Mar 1991 | A |
5158564 | Schnepp-Pesch et al. | Oct 1992 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5322064 | Lundquist | Jun 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5368592 | Stern et al. | Nov 1994 | A |
5399164 | Snoke et al. | Mar 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5433742 | Willis | Jul 1995 | A |
5441483 | Avitall | Aug 1995 | A |
5445148 | Jaraczewski et al. | Aug 1995 | A |
5454788 | Walker et al. | Oct 1995 | A |
5477856 | Lundquist | Dec 1995 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5545200 | Nguyen et al. | Aug 1996 | A |
5554114 | Wallace et al. | Sep 1996 | A |
5558643 | Samson et al. | Sep 1996 | A |
5571147 | Sluijter et al. | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5588964 | Imran et al. | Dec 1996 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5626576 | Janssen | May 1997 | A |
5628775 | Jackson et al. | May 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5695506 | Pike et al. | Dec 1997 | A |
5697928 | Walcott et al. | Dec 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5709874 | Hanson et al. | Jan 1998 | A |
5741429 | Donadio, III et al. | Apr 1998 | A |
5743903 | Stern et al. | Apr 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5807249 | Qin et al. | Sep 1998 | A |
5823955 | Kuck et al. | Oct 1998 | A |
5827272 | Breining et al. | Oct 1998 | A |
5860974 | Abele | Jan 1999 | A |
5865787 | Shapland | Feb 1999 | A |
5871444 | Ouchi | Feb 1999 | A |
5891114 | Chien et al. | Apr 1999 | A |
5893885 | Webster, Jr. | Apr 1999 | A |
5895378 | Berenstein et al. | Apr 1999 | A |
5904667 | Falwell | May 1999 | A |
5916214 | Cosio et al. | Jun 1999 | A |
5931830 | Jacobsen et al. | Aug 1999 | A |
5935102 | Bowden et al. | Aug 1999 | A |
5935124 | Klumb et al. | Aug 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5951539 | Nita et al. | Sep 1999 | A |
5954719 | Chen et al. | Sep 1999 | A |
5961511 | Mortier et al. | Oct 1999 | A |
5967978 | Littmann et al. | Oct 1999 | A |
5971975 | Mills et al. | Oct 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5983141 | Sluijter et al. | Nov 1999 | A |
5987344 | West | Nov 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6048338 | Larson et al. | Apr 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080171 | Keith et al. | Jun 2000 | A |
6090104 | Webster | Jul 2000 | A |
6091995 | Ingle et al. | Jul 2000 | A |
6099524 | Lipson et al. | Aug 2000 | A |
6102890 | Stlyland et al. | Aug 2000 | A |
6110187 | Donlon | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6135999 | Fanton et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6149620 | Baker et al. | Nov 2000 | A |
6159187 | Park et al. | Dec 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6165163 | Chien et al. | Dec 2000 | A |
6210362 | Ponzi | Apr 2001 | B1 |
6210406 | Webster | Apr 2001 | B1 |
6219577 | Brown, III et al. | Apr 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6245020 | Moore et al. | Jun 2001 | B1 |
6245045 | Stratienko | Jun 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6246914 | De La Rama et al. | Jun 2001 | B1 |
6254588 | Jones et al. | Jul 2001 | B1 |
6263224 | West | Jul 2001 | B1 |
6273876 | Klima et al. | Aug 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283960 | Ashley | Sep 2001 | B1 |
6287301 | Thompson et al. | Sep 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6298256 | Meyer | Oct 2001 | B1 |
6299623 | Wulfman | Oct 2001 | B1 |
6314325 | Fitz | Nov 2001 | B1 |
6322558 | Taylor et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6371965 | Gifford, III et al. | Apr 2002 | B2 |
6387105 | Gifford, III et al. | May 2002 | B1 |
6401720 | Stevens et al. | Jun 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6427089 | Knowlton | Jul 2002 | B1 |
6443965 | Gifford, III et al. | Sep 2002 | B1 |
6451034 | Gifford, III et al. | Sep 2002 | B1 |
6454775 | Demarais et al. | Sep 2002 | B1 |
6482202 | Goble et al. | Nov 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6491705 | Gifford, III et al. | Dec 2002 | B2 |
6497711 | Plaia et al. | Dec 2002 | B1 |
6500172 | Panescu et al. | Dec 2002 | B1 |
6506189 | Rittman et al. | Jan 2003 | B1 |
6508804 | Sarge et al. | Jan 2003 | B2 |
6514226 | Levin et al. | Feb 2003 | B1 |
6514236 | Stratienko | Feb 2003 | B1 |
6517572 | Kugler et al. | Feb 2003 | B2 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6542781 | Koblish et al. | Apr 2003 | B1 |
6549800 | Atalar et al. | Apr 2003 | B1 |
6562034 | Edwards et al. | May 2003 | B2 |
6565582 | Gifford, III et al. | May 2003 | B2 |
6569177 | Dillard et al. | May 2003 | B1 |
6585718 | Hayzelden et al. | Jul 2003 | B2 |
6610046 | Usami et al. | Aug 2003 | B1 |
6611720 | Hata et al. | Aug 2003 | B2 |
6613046 | Jenkins et al. | Sep 2003 | B1 |
6616624 | Kieval | Sep 2003 | B1 |
6622731 | Daniel et al. | Sep 2003 | B2 |
6628976 | Fuimaono et al. | Sep 2003 | B1 |
6632193 | Davison et al. | Oct 2003 | B1 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6648854 | Patterson et al. | Nov 2003 | B1 |
6651672 | Roth | Nov 2003 | B2 |
6656195 | Peters et al. | Dec 2003 | B2 |
6659981 | Stewart et al. | Dec 2003 | B2 |
6669670 | Muni et al. | Dec 2003 | B1 |
6669692 | Nelson et al. | Dec 2003 | B1 |
6676678 | Gifford, III et al. | Jan 2004 | B2 |
6679268 | Stevens et al. | Jan 2004 | B2 |
6682541 | Gifford, III et al. | Jan 2004 | B1 |
6685648 | Flaherty et al. | Feb 2004 | B2 |
6695857 | Gifford | Feb 2004 | B2 |
6699257 | Gifford, III et al. | Mar 2004 | B2 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6706010 | Miki et al. | Mar 2004 | B1 |
6711444 | Koblish | Mar 2004 | B2 |
6716207 | Farnholtz | Apr 2004 | B2 |
6723043 | Kleernan et al. | Apr 2004 | B2 |
6736835 | Pellegrino et al. | May 2004 | B2 |
6745080 | Koblish | Jun 2004 | B2 |
6749560 | Konstorum et al. | Jun 2004 | B1 |
6752805 | Maguire et al. | Jun 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6790206 | Panescu | Sep 2004 | B2 |
6829497 | Mogul | Dec 2004 | B2 |
6830568 | Kesten et al. | Dec 2004 | B1 |
6845267 | Harrison et al. | Jan 2005 | B2 |
6849075 | Bertolero et al. | Feb 2005 | B2 |
6850801 | Kieval et al. | Feb 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6884260 | Kugler et al. | Apr 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6889694 | Hooven | May 2005 | B2 |
6890329 | Carroll et al. | May 2005 | B2 |
6893436 | Woodard et al. | May 2005 | B2 |
6909009 | Koridze | Jun 2005 | B2 |
6915806 | Pacek et al. | Jul 2005 | B2 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6923808 | Taimisto | Aug 2005 | B2 |
6926669 | Stewart et al. | Aug 2005 | B1 |
6926713 | Rioux et al. | Aug 2005 | B2 |
6939346 | Kannenberg et al. | Sep 2005 | B2 |
6945956 | Waldhauser et al. | Sep 2005 | B2 |
6949097 | Stewart et al. | Sep 2005 | B2 |
6955175 | Stevens et al. | Oct 2005 | B2 |
6966908 | Maguire et al. | Nov 2005 | B2 |
6984238 | Gifford, III et al. | Jan 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7087051 | Bourne et al. | Aug 2006 | B2 |
7100614 | Stevens et al. | Sep 2006 | B2 |
7102151 | Reinberg et al. | Sep 2006 | B2 |
7110828 | Kolberg et al. | Sep 2006 | B2 |
7112211 | Gifford, III et al. | Sep 2006 | B2 |
7115183 | Larson | Oct 2006 | B2 |
7137990 | Hebert et al. | Nov 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7153315 | Miller | Dec 2006 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7172610 | Heitzmann et al. | Feb 2007 | B2 |
7184811 | Phan et al. | Feb 2007 | B2 |
7192427 | Chapelon et al. | Mar 2007 | B2 |
7221979 | Zhou et al. | May 2007 | B2 |
7238184 | Megerman et al. | Jul 2007 | B2 |
7241273 | Maguire et al. | Jul 2007 | B2 |
7276062 | McDaniel et al. | Oct 2007 | B2 |
7294127 | Leung et al. | Nov 2007 | B2 |
7311705 | Sra | Dec 2007 | B2 |
7338467 | Lutter | Mar 2008 | B2 |
7367972 | Francischelli et al. | May 2008 | B2 |
7381200 | Katoh et al. | Jun 2008 | B2 |
7390894 | Weinshilboum et al. | Jun 2008 | B2 |
7393338 | Nita | Jul 2008 | B2 |
7402151 | Rosenman et al. | Jul 2008 | B2 |
7486805 | Krattiger | Feb 2009 | B2 |
7488338 | Eidenschink | Feb 2009 | B2 |
7494486 | Mische et al. | Feb 2009 | B2 |
7494488 | Weber et al. | Feb 2009 | B2 |
7497858 | Chapelon et al. | Mar 2009 | B2 |
7517349 | Truckai et al. | Apr 2009 | B2 |
7520863 | Grewe et al. | Apr 2009 | B2 |
7540865 | Griffin et al. | Jun 2009 | B2 |
7563247 | Maguire et al. | Jul 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7637903 | Lentz et al. | Dec 2009 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7682319 | Martin et al. | Mar 2010 | B2 |
7699809 | Urmey | Apr 2010 | B2 |
7706894 | Stewart et al. | Apr 2010 | B2 |
7708704 | Mitelberg et al. | May 2010 | B2 |
7717853 | Nita | May 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7727187 | Lentz | Jun 2010 | B2 |
7758520 | Griffin et al. | Jul 2010 | B2 |
7763012 | Petrick et al. | Jul 2010 | B2 |
7771410 | Venturelli | Aug 2010 | B2 |
7771421 | Stewart et al. | Aug 2010 | B2 |
7778703 | Gross et al. | Aug 2010 | B2 |
7780660 | Bourne et al. | Aug 2010 | B2 |
7785289 | Rios et al. | Aug 2010 | B2 |
7806871 | Li et al. | Oct 2010 | B2 |
7811265 | Hering et al. | Oct 2010 | B2 |
7811281 | Rentrop | Oct 2010 | B1 |
7815637 | Ormsby et al. | Oct 2010 | B2 |
7819866 | Bednarek | Oct 2010 | B2 |
7846157 | Kozel | Dec 2010 | B2 |
7850685 | Kunis et al. | Dec 2010 | B2 |
7862565 | Eder et al. | Jan 2011 | B2 |
7863897 | Slocum, Jr. et al. | Jan 2011 | B2 |
7896873 | Hiller et al. | Mar 2011 | B2 |
7905862 | Sampson | Mar 2011 | B2 |
7938830 | Saadat et al. | May 2011 | B2 |
7967816 | Ocel et al. | Jun 2011 | B2 |
7989042 | Obara et al. | Aug 2011 | B2 |
8007440 | Magnin et al. | Aug 2011 | B2 |
8007462 | Gibson et al. | Aug 2011 | B2 |
8027718 | Spinner et al. | Sep 2011 | B2 |
8043288 | Dando et al. | Oct 2011 | B2 |
8075580 | Makower | Dec 2011 | B2 |
8088127 | Mayse et al. | Jan 2012 | B2 |
8092444 | Lentz et al. | Jan 2012 | B2 |
8124876 | Dayton et al. | Feb 2012 | B2 |
8131371 | Demarais et al. | Mar 2012 | B2 |
8131372 | Levin et al. | Mar 2012 | B2 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8145317 | Demarais et al. | Mar 2012 | B2 |
8150518 | Levin et al. | Apr 2012 | B2 |
8150519 | Demarais et al. | Apr 2012 | B2 |
8150520 | Demarais et al. | Apr 2012 | B2 |
8172829 | Farnholtz | May 2012 | B2 |
8175711 | Demarais et al. | May 2012 | B2 |
8190238 | Moll et al. | May 2012 | B2 |
8241217 | Chiang et al. | Aug 2012 | B2 |
8251977 | Partlett | Aug 2012 | B2 |
8292881 | Brannan et al. | Oct 2012 | B2 |
8343145 | Brannan | Jan 2013 | B2 |
8366615 | Razavi | Feb 2013 | B2 |
8376865 | Forster et al. | Feb 2013 | B2 |
8388680 | Starksen et al. | Mar 2013 | B2 |
8398629 | Thistle | Mar 2013 | B2 |
8401650 | Simon et al. | Mar 2013 | B2 |
8409193 | Young et al. | Apr 2013 | B2 |
8409195 | Young | Apr 2013 | B2 |
8418362 | Zerfas et al. | Apr 2013 | B2 |
8473023 | Worley et al. | Jun 2013 | B2 |
8485992 | Griffin et al. | Jul 2013 | B2 |
8486060 | Kotmel et al. | Jul 2013 | B2 |
8486063 | Werneth et al. | Jul 2013 | B2 |
8740849 | Fischell et al. | Jun 2014 | B1 |
8817999 | Moeller et al. | Aug 2014 | B2 |
8974451 | Smith | Mar 2015 | B2 |
9162046 | Hill et al. | Oct 2015 | B2 |
10166069 | Tran | Jan 2019 | B2 |
20020022864 | Mahvi et al. | Feb 2002 | A1 |
20020062123 | McClurken et al. | May 2002 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020107515 | Edwards et al. | Aug 2002 | A1 |
20020139379 | Edwards et al. | Oct 2002 | A1 |
20020165532 | Hill, III et al. | Nov 2002 | A1 |
20020183682 | Darvish et al. | Dec 2002 | A1 |
20030004510 | Wham et al. | Jan 2003 | A1 |
20030050635 | Truckai et al. | Mar 2003 | A1 |
20030050681 | Pianca et al. | Mar 2003 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030065317 | Rudie et al. | Apr 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030092995 | Thompson | May 2003 | A1 |
20030125790 | Fastovsky et al. | Jul 2003 | A1 |
20030139689 | Shturman et al. | Jul 2003 | A1 |
20030181897 | Thomas et al. | Sep 2003 | A1 |
20030195507 | Stewart et al. | Oct 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20030220639 | Chapelon et al. | Nov 2003 | A1 |
20030229340 | Sherry et al. | Dec 2003 | A1 |
20030233099 | Danaek et al. | Dec 2003 | A1 |
20040006359 | Laguna | Jan 2004 | A1 |
20040010289 | Biggs et al. | Jan 2004 | A1 |
20040030375 | Pierce | Feb 2004 | A1 |
20040073206 | Foley et al. | Apr 2004 | A1 |
20040088002 | Boyle et al. | May 2004 | A1 |
20040167509 | Taimisto | Aug 2004 | A1 |
20040215186 | Cornelius et al. | Oct 2004 | A1 |
20050004515 | Hart et al. | Jan 2005 | A1 |
20050010095 | Stewart et al. | Jan 2005 | A1 |
20050080409 | Young et al. | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050187579 | Danek et al. | Aug 2005 | A1 |
20050228286 | Messerly et al. | Oct 2005 | A1 |
20050228460 | Levin et al. | Oct 2005 | A1 |
20050273006 | Stewart et al. | Dec 2005 | A1 |
20060004323 | Chang et al. | Jan 2006 | A1 |
20060004346 | Begg | Jan 2006 | A1 |
20060025765 | Landman et al. | Feb 2006 | A1 |
20060074403 | Rafiee | Apr 2006 | A1 |
20060085054 | Zikorus et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060095029 | Young et al. | May 2006 | A1 |
20060122587 | Sharareh | Jun 2006 | A1 |
20060142753 | Francischelli et al. | Jun 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060184221 | Stewart et al. | Aug 2006 | A1 |
20060206150 | Demarais et al. | Sep 2006 | A1 |
20060212076 | Demarais et al. | Sep 2006 | A1 |
20060224153 | Fischell et al. | Oct 2006 | A1 |
20060263393 | Demopulos et al. | Nov 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20060276846 | Malecki et al. | Dec 2006 | A1 |
20060287644 | Inganas et al. | Dec 2006 | A1 |
20070027390 | Maschke et al. | Feb 2007 | A1 |
20070049924 | Rahn | Mar 2007 | A1 |
20070067008 | Scheiner et al. | Mar 2007 | A1 |
20070073151 | Lee | Mar 2007 | A1 |
20070100405 | Thompson et al. | May 2007 | A1 |
20070106247 | Burnett et al. | May 2007 | A1 |
20070112327 | Yun et al. | May 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070149963 | Matsukuma et al. | Jun 2007 | A1 |
20070156114 | Worley et al. | Jul 2007 | A1 |
20070179496 | Swoyer et al. | Aug 2007 | A1 |
20070197891 | Shachar et al. | Aug 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20070270779 | Jacobs et al. | Nov 2007 | A1 |
20080004658 | Malecki et al. | Jan 2008 | A1 |
20080015562 | Hong et al. | Jan 2008 | A1 |
20080071269 | Hilario et al. | Mar 2008 | A1 |
20080077119 | Snyder et al. | Mar 2008 | A1 |
20080086047 | McDaniel et al. | Apr 2008 | A1 |
20080091193 | Kauphusman et al. | Apr 2008 | A1 |
20080108867 | Zhou | May 2008 | A1 |
20080140072 | Stangenes et al. | Jun 2008 | A1 |
20080177205 | Rama et al. | Jul 2008 | A1 |
20080287918 | Rosenman et al. | Nov 2008 | A1 |
20080319513 | Pu et al. | Dec 2008 | A1 |
20090012465 | Latini | Jan 2009 | A1 |
20090030312 | Hadjicostis | Jan 2009 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090043372 | Northrop et al. | Feb 2009 | A1 |
20090069671 | Anderson | Mar 2009 | A1 |
20090118620 | Tgavalekos et al. | May 2009 | A1 |
20090149848 | Werneth et al. | Jun 2009 | A1 |
20090157048 | Sutermeister et al. | Jun 2009 | A1 |
20090163850 | Betts et al. | Jun 2009 | A1 |
20090171333 | Hon | Jul 2009 | A1 |
20090221955 | Babaev | Sep 2009 | A1 |
20090306650 | Govari et al. | Dec 2009 | A1 |
20090312606 | Dayton et al. | Dec 2009 | A1 |
20100030061 | Canfield et al. | Feb 2010 | A1 |
20100069882 | Jennings et al. | Mar 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100168740 | Stewart et al. | Jul 2010 | A1 |
20100179512 | Chong et al. | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100217184 | Koblish et al. | Aug 2010 | A1 |
20100222851 | Deem et al. | Sep 2010 | A1 |
20100222854 | Demarais et al. | Sep 2010 | A1 |
20100249604 | Hastings et al. | Sep 2010 | A1 |
20100312141 | Keast et al. | Dec 2010 | A1 |
20100324482 | Farnholtz | Dec 2010 | A1 |
20110021976 | Li et al. | Jan 2011 | A1 |
20110028962 | Werneth et al. | Feb 2011 | A1 |
20110034989 | Al-Marashi et al. | Feb 2011 | A1 |
20110054464 | Werneth et al. | Mar 2011 | A1 |
20110054465 | Werneth et al. | Mar 2011 | A1 |
20110071400 | Hastings et al. | Mar 2011 | A1 |
20110071401 | Hastings et al. | Mar 2011 | A1 |
20110112476 | Kauphusman et al. | May 2011 | A1 |
20110270173 | Gibson et al. | Nov 2011 | A1 |
20120059241 | Hastings et al. | Mar 2012 | A1 |
20120130289 | Demarais et al. | May 2012 | A1 |
20120130345 | Levin et al. | May 2012 | A1 |
20120172837 | Demarais et al. | Jul 2012 | A1 |
20120197246 | Mauch | Aug 2012 | A1 |
20120265066 | Crow et al. | Oct 2012 | A1 |
20130035681 | Subramaniam et al. | Feb 2013 | A1 |
20130090647 | Smith | Apr 2013 | A1 |
20130090649 | Smith et al. | Apr 2013 | A1 |
20130090651 | Smith | Apr 2013 | A1 |
20130090652 | Jenson | Apr 2013 | A1 |
20130096550 | Hill | Apr 2013 | A1 |
20130096553 | Hill et al. | Apr 2013 | A1 |
20130096554 | Groff et al. | Apr 2013 | A1 |
20130123770 | Smith | May 2013 | A1 |
20130131667 | Jenson et al. | May 2013 | A1 |
20130150808 | Ogle et al. | Jun 2013 | A1 |
20130172879 | Sutermeister et al. | Jul 2013 | A1 |
20130172881 | Hill et al. | Jul 2013 | A1 |
20130184642 | O'Donnell et al. | Jul 2013 | A1 |
20130184703 | Shireman et al. | Jul 2013 | A1 |
20130237780 | Beasley et al. | Sep 2013 | A1 |
20130274730 | Anderson et al. | Oct 2013 | A1 |
20130274731 | Anderson et al. | Oct 2013 | A1 |
20130274737 | Wang et al. | Oct 2013 | A1 |
20130304061 | Chang et al. | Nov 2013 | A1 |
20140094787 | Reynolds | Apr 2014 | A1 |
20140121641 | Fischell et al. | May 2014 | A1 |
20140121644 | Fischell et al. | May 2014 | A1 |
20140135755 | Sutermeister et al. | May 2014 | A1 |
20140214026 | Degen | Jul 2014 | A1 |
20140249524 | Kocur | Sep 2014 | A1 |
20140276613 | Goodman et al. | Sep 2014 | A1 |
20140276752 | Wang et al. | Sep 2014 | A1 |
20140276787 | Wang et al. | Sep 2014 | A1 |
20140358079 | Fischell et al. | Dec 2014 | A1 |
20140378967 | Willard et al. | Dec 2014 | A1 |
20150265339 | Lindquist et al. | Sep 2015 | A1 |
20180042672 | Heisel et al. | Feb 2018 | A1 |
Number | Date | Country |
---|---|---|
2782017 | May 2006 | CN |
201375561 | Jan 2010 | CN |
102125460 | Jul 2011 | CN |
102125725 | Jul 2011 | CN |
102885648 | Jan 2013 | CN |
102885649 | Jan 2013 | CN |
102908188 | Feb 2013 | CN |
102908189 | Feb 2013 | CN |
102005041601 | Apr 2007 | DE |
102012104705 | Dec 2013 | DE |
0348136 | Dec 1989 | EP |
0352955 | Jan 1990 | EP |
0647435 | Apr 1995 | EP |
0652026 | May 1995 | EP |
0664990 | Aug 1995 | EP |
0680351 | Nov 1995 | EP |
0512359 | Dec 1996 | EP |
0787019 | Aug 1997 | EP |
0542246 | Sep 1997 | EP |
0834289 | Apr 1998 | EP |
0862478 | Sep 1998 | EP |
0937481 | Aug 1999 | EP |
0944353 | Sep 1999 | EP |
0951244 | Oct 1999 | EP |
0984806 | Mar 2000 | EP |
0626818 | May 2002 | EP |
0727184 | Dec 2002 | EP |
1286625 | Mar 2003 | EP |
1374943 | Jan 2004 | EP |
1656963 | May 2006 | EP |
1709922 | Oct 2006 | EP |
1768732 | Apr 2007 | EP |
1787674 | May 2007 | EP |
1824548 | Aug 2007 | EP |
1827558 | Sep 2007 | EP |
1857134 | Nov 2007 | EP |
1906853 | Apr 2008 | EP |
1968679 | Sep 2008 | EP |
2027882 | Feb 2009 | EP |
1326550 | Sep 2009 | EP |
2320821 | May 2011 | EP |
2340765 | Jul 2011 | EP |
2389974 | Nov 2011 | EP |
2398540 | Dec 2011 | EP |
2445568 | May 2012 | EP |
2747688 | Jul 2014 | EP |
2759314 | Jul 2014 | EP |
2804554 | Nov 2014 | EP |
2900160 | Aug 2015 | EP |
2900161 | Aug 2015 | EP |
2990070 | Mar 2016 | EP |
3010436 | Apr 2016 | EP |
2768563 | Nov 2016 | EP |
WO1991001772 | Feb 1991 | WO |
WO1992015356 | Sep 1992 | WO |
WO1994007446 | Apr 1994 | WO |
WO1994019039 | Sep 1994 | WO |
WO1994028809 | Dec 1994 | WO |
WO1995025472 | Sep 1995 | WO |
WO1995031142 | Nov 1995 | WO |
WO1997029800 | Aug 1997 | WO |
WO1997036548 | Oct 1997 | WO |
WO1997048435 | Dec 1997 | WO |
WO1998042403 | Oct 1998 | WO |
WO 1998043530 | Oct 1998 | WO |
WO1998048885 | Nov 1998 | WO |
WO 1998050098 | Nov 1998 | WO |
WO1998052637 | Nov 1998 | WO |
WO1999000060 | Jan 1999 | WO |
WO1999011313 | Mar 1999 | WO |
WO2001022897 | Apr 2001 | WO |
WO2001037723 | May 2001 | WO |
WO2001037746 | May 2001 | WO |
WO2001070114 | Sep 2001 | WO |
WO2002030310 | Apr 2002 | WO |
WO2002080766 | Oct 2002 | WO |
WO2002089908 | Nov 2002 | WO |
WO2003022167 | Mar 2003 | WO |
WO2003082080 | Oct 2003 | WO |
WO2014036163 | Mar 2004 | WO |
WO2005030072 | Apr 2005 | WO |
WO2005041748 | May 2005 | WO |
WO2005110528 | Nov 2005 | WO |
WO2006009588 | Jan 2006 | WO |
WO2006041881 | Apr 2006 | WO |
WO2006065949 | Jun 2006 | WO |
WO2006105121 | Oct 2006 | WO |
WO2007008954 | Jan 2007 | WO |
WO2007059277 | May 2007 | WO |
WO2007078997 | Jul 2007 | WO |
WO2007117359 | Oct 2007 | WO |
WO2008010150 | Jan 2008 | WO |
WO2008036281 | Mar 2008 | WO |
WO2008049084 | Apr 2008 | WO |
WO2008064399 | Jun 2008 | WO |
WO2008101244 | Aug 2008 | WO |
WO2008139347 | Nov 2008 | WO |
WO2009082635 | Jul 2009 | WO |
WO2009088678 | Jul 2009 | WO |
WO2009137819 | Nov 2009 | WO |
WO2010091701 | Aug 2010 | WO |
WO2010134503 | Nov 2010 | WO |
WO2011056311 | May 2011 | WO |
WO2012100095 | Jul 2012 | WO |
WO2013016203 | Jan 2013 | WO |
WO2013055537 | Apr 2013 | WO |
WO2013055685 | Apr 2013 | WO |
WO2013055815 | Apr 2013 | WO |
WO2013055826 | Apr 2013 | WO |
WO2013056672 | Apr 2013 | WO |
WO2013058962 | Apr 2013 | WO |
WO2013106054 | Jul 2013 | WO |
WO2013109318 | Jul 2013 | WO |
WO2013158676 | Oct 2013 | WO |
WO2013158678 | Oct 2013 | WO |
WO2014012282 | Jan 2014 | WO |
WO2014174662 | Oct 2014 | WO |
WO2016090175 | Jun 2016 | WO |
Entry |
---|
Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardicvascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
Avetall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984. |
Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages. |
Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831. |
Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246. |
Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages). |
Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198. |
Opposition to European Patent No. 2465470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp. |
Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 24 pages. |
Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages. |
Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages. |
Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2103278,00.htm>. |
Papademetriou, Vasillios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
Pieper, et al., “Design and Implementation of a New Computerized System for Intraoperative Cardiac Mapping” Journal of Applied Physiology, 1991; vol. 71 (4), pp. 1529-1539. |
Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages. |
Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005. |
Remo, et al., “Safety and Efficacy of Renal Denervation as a Novel Treatment of Ventricular Tachycardia Storm in Patients with Cardiomyopathy” Heart Rhythm 2014, 11(4), pp. 541-546. |
Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003). |
ThermaCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp. |
U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, 62 pgs. |
U.S. Appl. No. 60/852,787, filed Oct. 18, 2006, 112 pgs. |
Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pgs. |
Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968. |
Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410. |
U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
“2011 Edison Award Winners,” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct_2011.php>. |
“2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
“Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
“Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>. |
“Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages. <http://my.clevelandclinic.org/media_relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
“Does renal represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages. <http://www.cxvascular.com/in-latest-news/interventional-news—latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertention>. |
“Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
“Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page. <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
“Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
“Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
“The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
“The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
“Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
Asbell, Penny, “Conductive Keratoplasty for the Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Intergr Comp Physiol, vol. 274, 1998, 7 pages. |
Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplation: A logitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999, 7 pages. |
Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals from the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global Symplicity registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid83002>. |
Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
Final Office Action; U.S. Appl. No. 12/827,700; dated Feb. 5, 2013, 61 pages. |
Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages. |
Gertner, Jon, “Meet the Tech Duo That's Revitalizing The Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/rneet-tech-duo-thats-revitalizing-medical-device-industry>. |
Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
Han, Y.-M, et al., “Renal artery embolization with diluted hot contrast medium: An experimental study,” J Vasc Interv Radiol, 12: 862-868 (2001). |
Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages. |
Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
Imimdtanz, “Medtronic awarded industry's highest honor for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-systems/>. |
Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
Lee, S. J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
Lustgarten, D. L., et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
Mahfoud Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages. |
Millard, F. C., et al, “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension 19:II-17-II-21 (1992). |
Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004,” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial,” EuroIntervention, vol. 9, 2013, 5 pages. |
Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=80880>. |
Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J surgery (1948) pp. 48-68. |
Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
Sievert, Horst, “Novelity Award EuroPCR 2010.” Euro PCR, 2010, 15 pages. |
Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
Stouffer, G.A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
Swartz, J. F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation; A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
Miller, Reed, “Finding a Future for Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article # 01141006003, Oct. 6, 2014, 4 pages. |
Papademetriou, Vasilios; “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214. |
Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129: 1440-1450. |
Papademetriou, Vasilios et al., “Catheter-Based Renal for Resistant Hypertension: 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System.” Hypertension, 2014; 64: 565-572. |
Doumas, Michael et al., “Renal Nerve ablation for Resistant Hypertension: The Dust Has Not Yet Settled,” The Journal of Clinical Hypertension, 2014; vol. 16, No. 6, 2 pages. |
Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages. |
Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” Journal of Clinical Investigation, vol. 56, Jul. 1975, pp. 208-217. |
Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1104-1107. |
Bhandari, A. and Ellias, M., “Loin Pain Hematuria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Clinc, 2000, vol. 12, No. 4, pp. 323-327. |
Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981). |
Dibona, Gerald F. et al., “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, The American Physiological Society 1997, pp. 75-197. |
Dibona, Gerald F., “Neural Control of the Kidney—Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrarenal Norepinephrine Infusion in Conscious Rats”, Journal of Hypertension 1989, 7: 447-455. |
Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. vol. 245, 1983, The American Physiological Society 1983, pp. F1-F14. |
Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81. |
Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages. |
Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347. |
Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731. |
Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. |
Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458. |
Page, I.H. et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30. |
Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009, 4 pages. |
Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept,” Hypertension, 2009; 54:1195-1201. |
Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934. |
Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504. |
Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917. |
Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909. |
United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages. |
Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page. |
Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 The American Physiological Society, pp. 2034-2039. |
Medtronic, “Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter,” Instructions for Use, Jul. 2016, Doc No. M967336A001, Rev. 1A, 144 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/013042; dated Apr. 7, 2015; 10 pages. |
Number | Date | Country | |
---|---|---|---|
20190117302 A1 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
61932224 | Jan 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14606821 | Jan 2015 | US |
Child | 16229147 | US |